FSD Pharma (NASDAQ:HUGE) Rating Reiterated by Singular Research

FSD Pharma (NASDAQ:HUGE)‘s stock had its “buy-venture” rating restated by investment analysts at Singular Research in a research note issued to investors on Tuesday, Zacks.com reports. Singular Research also issued estimates for FSD Pharma’s Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.12) EPS.

FSD Pharma Stock Down 4.3 %

NASDAQ HUGE opened at $0.35 on Tuesday. The firm has a market cap of $13.97 million, a PE ratio of -0.74 and a beta of 0.71. FSD Pharma has a 52 week low of $0.34 and a 52 week high of $1.68. The company has a 50 day moving average price of $0.63 and a 200 day moving average price of $0.86.

FSD Pharma (NASDAQ:HUGE) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.04) EPS for the quarter.

Institutional Trading of FSD Pharma

An institutional investor recently raised its position in FSD Pharma stock. AdvisorShares Investments LLC grew its position in FSD Pharma Inc. (NASDAQ:HUGE) by 14.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 270,316 shares of the company’s stock after purchasing an additional 34,679 shares during the period. AdvisorShares Investments LLC owned approximately 0.69% of FSD Pharma worth $249,000 at the end of the most recent quarter. 1.24% of the stock is owned by institutional investors.

About FSD Pharma

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.